The Scientific and Clinical Development team at Asceneuron is responsible for advancing therapeutic candidates from preclinical stages through early clinical trials. This includes developing translational medicine strategies, overseeing preclinical development, assessing ADME (absorption, distribution, metabolism, and excretion) and toxicology, and guiding non-clinical development and medicinal chemistry efforts. Their ultimate goal is to ensure the safety, efficacy, and regulatory approval of novel treatments for orphan tauopathies and Alzheimer’s disease.
Adam Boxer
Scientific Advisor
Anna Quattropani
Head of Non-Clinical Developme...
Bruno Permanne
Senior Director & Head of Prec...
Christian Haass
Scientific Advisor
Günter U. Höglinger
Scientific Advisor
Manfred Schneider
Head of ADME & Toxicology
Pearl Fang
VP & Head of Clinical Developm...
Raymond G. Hill
Scientific Advisor
Rolf Pokorny
Head of Early Clinical Develop...
Ryan Schubert
SVP, Translational Medicine & ...
View all